- What else after the failure of the first line EFGR-TKI treatment2015 | Faculty of Medicine in Pilsen
- Treatment of metastatic renal cell carcinoma in higher lines - patients after progression on TKI and immune checkpoint inhibitor2022 | First Faculty of Medicine
- KRAS (G12S) mutation in a patient with NSCLC treated with erlotinib – a case report2013 | Faculty of Medicine in Pilsen
- Possible discontinuation of treatment by tyrosine kinase inhibitors in patients with chronic myeloid leukemia and concept of treatment-free remission2017 | Publication without faculty affiliation
- Lung adenocarcinoma with two simultaneous driving mutations2013 | Faculty of Medicine in Pilsen
- Osimertinib - a new oral third-generation EGFR TKI2017 | Publication without faculty affiliation
- Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC2013 | Faculty of Medicine in Pilsen
- Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation2015 | Faculty of Medicine in Pilsen, Faculty of Science
- The Role of Neuron-specific Enolase (NSE) and Thimidine Kinase (TK) Levels in Prediction of Efficacy of EGFR-TKIs in Patients with Advanced-stage NSCLC2014 | Faculty of Medicine in Pilsen
- Tolerancy of treatment with afatinib on our group of patients2014 | Faculty of Medicine in Pilsen
- Gene Mutations in Squamous Cell NSCLC: Insignificance of EGFR, KRAS and PIK3CA Mutations in Prediction of EGFR-TKI Treatment Efficacy2013 | Faculty of Medicine in Pilsen
- Where does treatment of chronic myeloid leukemia target tyrosine kinase inhibitors?2018 | First Faculty of Medicine
- Current treatment options for renal cell carcinoma and outlook2020 | Publication without faculty affiliation
- Current Two EGFR Mutations in Lung Adenocarcinoma - Case Report2015 | Faculty of Medicine in Pilsen, Faculty of Medicine in Hradec Králové
- Commnetary to the study2010 | First Faculty of Medicine
- Treatment of HER2-positive breast cancer in 20202020 | First Faculty of Medicine
- Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party2021 | Publication without faculty affiliation
- Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial2018 | Publication without faculty affiliation
- EGFR mutations in patients with advanced NSCLC2012 | Faculty of Medicine in Pilsen
- Current position of afatinib in the therapy of non-small cell lung carcinoma2017 | Publication without faculty affiliation
- Afatinib - drug profile2017 | Publication without faculty affiliation
- Lorlatinib in the treatment of non‑small cell lung cancer2020 | Publication without faculty affiliation
- Discontinuation of biological therapy with tyrosine kinase inhibitors in chronic myeloid leukemia patients2014 | Faculty of Medicine in Pilsen
- Erlotinib in the treatment of advanced squamous cell NSCLC2013 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Serum albumin is a strong predictor of survival in patients with advanced-stage non-small cell lung cancer treated with erlotinib2016 | Faculty of Medicine in Pilsen, Faculty of Science
- Patient with three EGFR mutations - gradual development of resistance to previous targeted treatment2018 | Faculty of Medicine in Pilsen, Faculty of Science
- Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor2019 | Second Faculty of Medicine
- High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib2015 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Science
- Two years longer and peaceful life thanks to alectinib2022 | Third Faculty of Medicine, Central Library of Charles University
- Results of the evaluation of osimertinib in previously non-treated patients with EGFR-mutated advanced NSCLC: FLAURA study2018 | First Faculty of Medicine